Antiretroviral therapy response among HIV-2 infected patients: A systematic review

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Ekouevi, Didier K ^a,b,c,d   Tchounga, Boris K ^a,b,c   Coffie, Patrick A ^a,e,f   Tegbe, Joseph ^a   Anderson, Alexandra M ^a   Gottlieb, Geoffrey S ^g   Vitoria, Marco ^h   Dabis, Franҫois ^b,c   Eholie, Serge P ^a,e,f  

^a PACCI   (Côte d’Ivoire)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d UNIVERSITY OF LOMÉ   (Togo)

^e UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^g UNIVERSITY OF WASHINGTON   (United States)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antiretroviral treatment; Clinical response; HIV 2; Immunological response; Virological response

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; LOPINAVIR; RITONAVIR;

ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DRUG RESPONSE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNE RESPONSE; MORTALITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS LOAD; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CLINICAL TRIAL (TOPIC); FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 2; MALE; MIDDLE AGED; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HIV-2; HUMANS; INDINAVIR; LOPINAVIR; MALE; MIDDLE AGED; NELFINAVIR; RITONAVIR; TREATMENT OUTCOME;

EID: 84906819394     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-461     Document Type: Article

References (54)

1. da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, Anderssond S, Aaby P. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing?. AIDS 2008, 22(10):1195-1202.
2. Gianelli E, Riva A, Rankin Bravo FA, Da Silva TD, Mariani E, Casazza G, Scalamogna C, Bosisio O, Adorni F, Rusconi S, Galli M. Prevalence and risk determinants of HIV-1 and HIV-2 infections in pregnant women in Bissau. J Infect 2010, 61(5):391-398.
3. Mansson F, Camara C, Biai A, Monteiro M, da Silva ZJ, Dias F, Alves A, Andersson S, Fenyo¨ EM, Norrgren H, Unemo M. High prevalence of HIV-1, HIV-2 and other sexually transmitted infections among women attending two sexual health clinics in Bissau, Guinea-Bissau, West Africa. Int J STD AIDS 2010, 21(9):631-635.
4. Chang LW, Osei-Kwasi M, Boakye D, Aidoo S, Hagy A, Curran JW, Vermund SH. HIV-1 and HIV-2 seroprevalence and risk factors among hospital outpatients in the Eastern Region of Ghana, West Africa. J Acquir Immune Defic Syndr 2002, 29(5):511-516.
5. Rouet F, Ekouevi DK, Inwoley A, Chaix ML, Burgard M, Bequet L, Viho I, Leroy V, Simon F, Dabis F, Rouzioux C. Field evaluation of a rapid human immunodeficiency virus (HIV) serial serologic testing algorithm for diagnosis and differentiation of HIV type 1 (HIV-1), HIV-2, and dual HIV-1-HIV-2 infections in West African pregnant women. J Clin Microbiol 2004, 42(9):4147-4153.
6. Eholie S, Anglaret X. Commentary: decline of HIV-2 prevalence in West Africa: good news or bad news?. Int J Epidemiol 2006, 35(5):1329-1330.
7. Schmidt WP, Van Der Loeff MS, Aaby P, Whittle H, Bakker R, Buckner M, Dias F, White RG. Behaviour change and competitive exclusion can explain the diverging HIV-1 and HIV-2 prevalence trends in Guinea-Bissau. Epidemiol Infect 2008, 136(4):551-561.
8. Tienen C, van der Loeff MS, Zaman SM, Vincent T, Sarge-Njie R, Peterson I, Leligdowicz A, Jaye A, Rowland-Jones S, Aaby P, Whittle H. Two distinct epidemics: the rise of HIV-1 and decline of HIV-2 infection between 1990 and 2007 in rural Guinea-Bissau. J Acquir Immune Defic Syndr 2010, 53(5):640-647.
9. van der Loeff MF, Awasana AA, Sarge-Njie R, van der Sande M, Jaye A, Sabally S, Corrah T, McConkey SJ, Whittle HC. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 2006, 35(5):1322-1328.
10. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994, 265(5178):1587-1590.
11. Jaffar S, Wilkins A, Ngom PT, Sabally S, Corrah T, Bangali JE, Rolfe M, Whittle HC. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16(5):327-332.
12. Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, Dabis F, Brun-Vezinet F, Cheˆne G, Thie´baut R. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008, 22(4):457-468.
13. Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R, Whittle H. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1998, 1(7):457-468.
14. MacNeil A, Sarr AD, Sankale JL, Meloni ST, Mboup S, Kanki P. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007, 81(10):5325-5330.
15. Benard A, van Sighem A, Taieb A, Valadas E, Ruelle J, Soriano V, Calmy A, Balotta C, Damond F, Brun-Vezinet F, Chene G, Matheron S. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: the ACHI(E)V(2E) collaboration study group. Clin Infect Dis 2011, 52(10):1257-1266.
16. Martinez-Steele E, Awasana AA, Corrah T, Sabally S, van der Sande M, Jaye A, Togun T, Sarge-Njie R, McConkey SJ, Whittle H, van der Loeff MF S. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007, 21(3):317-324.
17. Harries K, Zachariah R, Manzi M, Firmenich P, Mathela R, Drabo J, Onadja G, Arnould L, Harries A. Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso. Trans R Soc Trop Med Hyg 2010, 104(2):154-161.
18. Peterson I, Togun O, de Silva T, Oko F, Rowland-Jones S, Jaye A, Peterson K. Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS 2011, 25(17):2167-2175.
19. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, Diakite N, Karcher S, Grundmann C, Marlink R, Dabis F, Anglaret X., Aconda Study Group Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 2008, 22(7):873-882. Aconda Study Group.
20. WHO Consolidated Guidelines On The Use Of Antiretroviral Drugs For Treating And Preventing Hiv Infection. Recommendations For A Public Health Approach 2013 Available from: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html. Accessed date 13 February 2014, WHO.
21. Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Massip P, Costagliola D, Katlama C, Brun-Vezinet F, Calvez V. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy. Antivir Ther 2001, 6(3):179-183.
22. Rodes B, Toro C, Sheldon JA, Jimenez V, Mansinho K, Soriano V. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 2006, 20(1):127-129.
23. Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, Ndour CT, Starling AK, Traore F, Sall F, Wong KG, Cherne SL, Anderson DJ, Dye SA, Smith RA, Mullins JI, Kiviat NB, Sow PS., University of Washington-Dakar HIV-2 Study Group Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis 2009, 48(4):476-483. University of Washington-Dakar HIV-2 Study Group.
24. Gottlieb GS, Hawes SE, Wong KG, Raugi DN, Agne HD, Critchlow CW, Kiviat NB, Sow PS. HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal. AIDS Res Hum Retroviruses 2008, 24(6):857-864.
25. Gottlieb GS, Smith RA, Dia Badiane NM, Ba S, Hawes SE, Toure M, Starling AK, Traore F, Sall F, Cherne SL, Stern J, Wong KG, Lu P, Kim M, Raugi DN, Lam A, Mullins JI, Kiviat NB., Sow PS for the UW-Dakar HIV-2 Study Group HIV-2 integrase variation in integrase inhibitor-naive adults in Senegal, West Africa. PLoS One 2011, 6(7):e22204. Sow PS for the UW-Dakar HIV-2 Study Group.
26. Gottlieb GS, Eholie SP, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle HC, Sow PS. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008, 22(16):2069-2072. discussion 73-4.
27. Matheron S. HIV-2 infection: a call for controlled trials. AIDS 2008, 22(16):2073-2074.
28. Benard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Ve´zinet F, Cheˆne G, Matheron S. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. AIDS 2009, 23(9):1171-1173.
29. van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD, Schutten M. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003, 17(Suppl 3):S55-S61.
30. Drylewicz J, Eholie S, Maiga M, Zannou DM, Sow PS, Ekouevi DK, Peterson K, Bissagnene E, Dabis F, Thie´baut R., International epidemiologic Databases to Evaluate AIDS (IeDEA) West Africa Collaboration First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. AIDS 2010, 24(7):1043-1050. International epidemiologic Databases to Evaluate AIDS (IeDEA) West Africa Collaboration.
31. Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, Cotten M, Vanham G, McConkey SJ, Rowland-Jones S, Janssens W. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol 2009, 47(7):2200-2208.
32. Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S, Corrah T, Whittle H, Vanham G, Rowland-Jones S, Janssens W, McConkey SJ. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 2006, 20(10):1455-1458.
33. Peterson K, Jallow S, Rowland-Jones SL, de Silva TI. Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. AIDS Res Treat 2011, 2011:463704.
34. Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, Eholie S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, Nolan M, Chorba T, Nkengasong JN HW. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003, 17(Suppl 3):S49-S54.
35. Gilleece Y, Chadwick DR, Breuer J, Hawkins D, Smit E, McCrae LX, Pillay D, Smith N, Anderson J., BHIVA Guidelines Subcommittee British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med 2010, 11(10):611-619. BHIVA Guidelines Subcommittee.
36. Morlat P. Prise en Charge Medicale Des Personnes Vivant Avec Le VIH. Recommandations Du Groupe D'experts. Rapport 2013. Sous la direction du Pr. Philippe Morlat et sous l'e´gide du CNS et de l'ANRS. 2013 Available from: http://www.sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf. Accesed date 13 February 2014.
37. New York State HIV Guidelines- NEW: Human Immunodeficiency Virus Type 2 (HIV-2) Available from: http://www.natap.org/2012/newsUpdates/041712_03.htm. Accesed date 13 February 2014.
38. Moher D, Liberati A, Tetzlaff J, Altman DG., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(7):e1000097. doi:10.1371/journal.pmed.1000097, PRISMA Group.
39. Mullins C, Eisen G, Popper S, Dieng Sarr A, Sankale JL, Berger JJ, Wright SB, Chang HR, Coste G, Cooley TP, Rice P, Skolnik PR, Sullivan M, Kanki PJ. Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis 2004, 38(12):1771-1779.
40. Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, Pueyo S, Brun-Vezinet F, Chene G., ANRS CO5 HIV2 Cohort Study Group CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006, 20(3):459-462. ANRS CO5 HIV2 Cohort Study Group.
41. Ndour CT, Batista G, Manga NM, Gueye NF, Badiane NM, Fortez L, Sow PS. Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: preliminary study. Med Mal Infect 2006, 36(2):111-114.
42. Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, Echahidi F, Pie´rard D, Verhofstede C, Van Laethem K, Delforge ML, Vaira D, Schmit JC, Goubau P. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis 2008, 8:21.
43. Smith CJ. Toward Optimal ART for HIV-2 Infection: Can Genotypic and Phenotypic Drug Resistance Testing Help Guide Therapy in HIV-2? (Paper # 579) 2010, San-Francisco, USA: 17th Conference on Retoviruses and Opportunistic Infections.
44. Chiara M, Rony Z, Homa M, Bhanumati V, Ladomirska J, Manzi M, Wilson N, Harries AD AD. Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai. Indian J Med Res 2010, 132:683-689.
45. Peterson K, Ruelle J, Vekemans M, Siegal FP, Deayton JR, Colebunders R. The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series. Antivir Ther 2012, 17(6):1097-1100.
46. Yeni P. Prise en charge me´dicale des personnes infecte´es par le VIH. Recommandations du groupe d'experts. Rapport 2010. Sous la direction du Pr. Patrick Yeni 2010 Available from: http://www.sante.gouv.fr/rapports,54.html. Accesed date 13 February 2014.
47. Ekouevi DK, Anglaret X, Coffie PA, Euge`ne M, Minga A, Eholie SP, Avettand-Fe´noe¨l V, Plantier JC, Damond F, Dabis F, Rouzioux C., for the IeDEA West Africa collaboration Plasma HIV-2 RNA According to CD4 Count Strata Among Untreated HIV-2-Infected Adults in Coˆte d'Ivoire: The IeDEA West Africa Collaboration. 7th International Aids Society Conference 30 June-3July 2013 Kuala Lumpur, Malaysia (abstract TUPE267), for the IeDEA West Africa collaboration.
48. Chang M, Gottlieb GS, Dragavon JA, Cherne SL, Kenney DL, Hawes SE, Smith RA, Kiviat NB, Sow PS, Coombs RW. Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform. J Clin Virol 2012, 55(2):128-133.
49. WHO Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach: 2010 Revision 2010, Available from: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accesed date 13 February 2014, WHO.
50. Balestre E, Eholie SP, Lokossue A, Sow PS, Charurat M, Minga A, Drabo J, Dabis F, Ekouevi DK, Thie´baut R., International epidemiological Database to Evaluate AIDS (IeDEA) West Africa Collaboration Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. AIDS 2012, 26(8):951-957. International epidemiological Database to Evaluate AIDS (IeDEA) West Africa Collaboration.
51. Smith RA, Anderson DJ, Pyrak CL, Preston BD, Gottlieb GS. Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis 2009, 199(9):1323-1326.
52. Charpentier C, Eholie´ S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoe¨l V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Ve´zinet F, Ekouevi DK., IeDEA West Africa Collaboration: Genotypic resistance profiles of HIV-2-treated patients in West Africa. AIDS 2014, 28(8):1161-1169. doi:10.1097/QAD.0000000000000244, IeDEA West Africa Collaboration:.
53. Matheron S, Descamps D, Boue F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP, Thiaux C., CNA3007 Study Group Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003, 8(2):163-171. CNA3007 Study Group.
54. Ekouevi DK, Balestre E, Coffie PA, Minta D, Messou E, Sawadogo A, Minga A, Sow PS, Bissagnene E, Eholie SP, Gottlieb GS, Dabis F., IeDEA West Africa collaboration Characteristics of HIV-2 and HIV-1/HIV-2 dually seropositive adults in West Africa presenting for care and antiretroviral therapy: the IeDEA-West Africa HIV-2 cohort study. PLoS One 2013, 8(6):e66135. IeDEA West Africa collaboration.